Neurodegeneration or dysfunction in Phelan-McDermid syndrome? A multimodal approach with CSF and computational MRI

• Published in: Orphanet journal of rare diseases 2023-09, Vol.18 (1), p.1-274, Article 274
• Main Authors: Jesse, Sarah, Müller, Hans-Peter, Huppertz, Hans-Jürgen, Andres, Stephanie, Ludolph, Albert C, Schön, Michael, Boeckers, Tobias M, Kassubek, Jan
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Amyloid; Amyloid-ß; Atrophy; Autism; Biomarkers; Brain; Cerebrospinal fluid; Chromosome 22; Chromosome deletion; Cingulum; Complications and side effects; Computational neuroscience; Corpus callosum; Degeneration; Diagnosis; Epidemiology; Fibers; Gene deletion; Inflammation; Magnetic resonance imaging; Medical research; Medicine, Experimental; Memory; Nervous system; Neural networks; Neurodegeneration; Neurodegenerative diseases; Pathophysiology; Patients; Phelan-McDermid syndrome; Positron emission tomography; Proteins; Pyramidal tracts; Rare diseases; SHANK3; Substantia alba; Substantia grisea; Tau protein
• ISSN: 1750-1172; 1750-1172
• DOI: 10.1186/s13023-023-02863-7

Phelan-McDermid syndrome (PMS) is a rare multisystem disease with global developmental delay and autistic features. Genetically, the disease is based on a heterozygous deletion of chromosome 22q13.3 with involvement of at least part of the SHANK3 gene or heterozygous pathogenic variants in SHANK3. Pathophysiologically, this syndrome has been regarded as a synaptopathy, but current data suggest an additional concept, since axonal functions of neurons are also impaired, thus, the specific pathophysiological processes in this disease are not yet fully understood. Since symptoms of the autism spectrum, regression, and stagnation in development occur, we investigated whether neuroinflammatory and neurodegenerative processes may also play a role. To this end, we analysed biomarkers in cerebrospinal fluid (CSF) and parameters from magnetic resonance imaging with high-resolution structural T1w volumetry and diffusion tensor imaging analysis in 19 Phelan-McDermid syndrome patients. CSF showed no inflammation but abnormalities in tau protein and amyloid-ss concentrations, however, with no typical biomarker pattern as in Alzheimer's disease. It could be demonstrated that these CSF changes were correlated with integrity losses of the fibres in the corticospinal tract as well as in the splenium and dorsal part of the cingulum. High CSF levels of tau protein were associated with loss of integrity of fibres in the corticospinal tract; lower levels of amyloid-ss were associated with decreasing integrity of fibre tracts of the splenium and posterior cingulate gyrus. Volumetric investigations showed global atrophy of the white matter, but not the grey matter, and particularly not in temporal or mesiotemporal regions, as is typical in later stages of Alzheimer's disease. In summary, alterations of neurodegenerative CSF markers in PMS individuals could be demonstrated which were correlated with structural connectivity losses of the corticospinal tract, the splenium, and the dorsal part of the cingulum, which can also be associated with typical clinical symptoms in these patients. These findings might represent a state of dysfunctional processes with ongoing degenerative and regenerative processes or a kind of accelerated aging. This study should foster further clinical diagnostics like tau- and amyloid-PET imaging as well as novel scientific approaches especially in basic research for further mechanistic proof.